Update to Recommendations to Protect Children Under Age 12, their Families and Communities
Building on the progress that has already been made with implementation of our first set of recommendations, the Vaccine Equity Cooperative Kids Vaccine Working Group created additional recommendations that respond to the slow progress of COVID-19 vaccinations for children, the decline in routine childhood immunizations, and the release of Omicron-specific boosters this fall.
In 2021, in anticipation of the COVID-19 vaccination rollout for children ages 5 to 11 years old, the Vaccine Equity Cooperative Kids Vaccine Working Group created a set of detailed recommendations to ensure all children, especially those who are most often underserved by existing systems, communities, receive equitable access to the COVID-19 vaccine. These recommendations rallied a diverse Working Group of concerned individuals and organizations in support of equitable vaccine coverage with a “no wrong door” approach.
In the fall of 2021, the Working Group met one-on-one with and then convened various government leaders at different stages of the vaccine rollout to help implement these recommendations and build and strengthen collaborations and connections for future partnerships. The Working Group appreciated the spirit of collaboration and support with which the recommendations were met, and the actions taken on the recommendations (e.g., reimbursement for vaccine counseling). Since then, the Working Group has continued to meet while tracking vaccine rollout and supporting uptake through our organizations and foundations.
Omicron cases and its variants continue to tax our vastly under-resourced health, public health, education and child care systems and personnel, with 14,195,580 total child COVID-19 cases reported, with children representing 18.5% (14,195,580/76,885,307) of all cases. Now that our children are returning to school and with only nascent research on the longer-term impacts of COVID-19 on children, we must take decisive action to protect them from COVID-19 and other diseases that can be addressed by routine immunizations.
Yet, COVID-19 vaccination rates remain low amongst children – especially very young children – with high state-by-state variability. A coordinated “all hands on deck” approach across federal and state agencies is critical at this time, in response to this dangerous gap in child vaccinations and the persistent disinformation designed to cast doubt in parents and guardians’ choices to vaccinate their children. The unprecedented silencing of experts who advocate for vaccines makes the battle to end vaccine-preventable diseases and keep children healthy that much more difficult. The recent resurgence of measles worldwide and polio in New York is further proof that the impact of anti-vaccination and disinformation campaigns are dangerously far-reaching and contributing to new health risks for a number diseases and populations.
Our national response to COVID-19 cannot regress. It must progress toward an equitable and comprehensive strategy to protect our children from any and all preventable infections, illnesses, hospitalizations and deaths. As funders and practitioners who are deeply committed to the health and well-being of children, we are grateful that there are safe and effective vaccines against COVID-19 for children from infancy through adolescence. We also recognize that uptake of this life-saving vaccine has been incomplete at best and inadequate at worst, to protect the nation, at every age group, from COVID-19 and its potential complications. This means that ideally vaccination efforts would focus on all age groups simultaneously.
However, in the face of foreshortened time, funds and public attention, we believe it is prudent to focus on vaccinating school-age children. This will help create safer learning environments for children who have already experienced significant learning disruption and loss over the past two years. This does not diminish the importance of vaccinating the 0 to 5 year old group, but rather presents an opportunity to gain traction among parents who have not yet vaccinated their school-age children. Focusing on families that include school-age children will ensure that, in the face of likely additional surges of COVID-19 in the fall and winter, these children can remain in school, safely. To build on the progress that has already been made with implementation of our first set of recommendations, the Working Group is providing additional recommendations that respond to the slow progress of COVID-19 vaccinations for children, the decline in routine childhood immunizations, and the release of Omicron-specific boosters this fall.
Short-term recommendations actionable over the next ~eight weeks:
In the near term, the Working Group suggests the following actions re: what can be done in the short term, with the Administration considering how to advance these actions promptly to ensure long-term value. If the federal government does not have these authorities, this group would like to discuss a mitigation plan.
1. Ensure the roles within the United States government are clearly defined and resourced for kids vaccines, COVID-19 response and school preparedness
While there has been proactive and well-intentioned activity, it is unclear how vaccine operations, coordination and communication operate within and across agencies including the CDC, HHS, and the White House – as well as the USDA and Department of Education. Creating a position for a singular lead across COVID-19 response and a singular point person for both routine childhood immunizations and COVID-19 vaccination will aid in resolving interagency, intra-agency, and external confusion about leadership, enhance coordination and communication across government agencies by establishing regular convenings, bolster public-private / nonprofit partnerships and support the empowered inclusion of trusted messengers on the ground (e.g., pediatricians, community health workers/Promotoras, educators and others). In addition, it will be critical to integrate the administration and resourcing of COVID-19 vaccination along with routine immunizations. The recent GAO report similarly calls for this kind of role and message clarity from HHS. Moreover, given the ongoing need, naming a singular lead should be implemented such that net capacity is added to the response team.
In addition, we recommend the childhood vaccination lead work in partnership with the American Academy of Pediatrics and others, including the National Association of School Nurses and National Association of Community Health Clinics, on all related kids vaccine communications and logistics for pediatricians to inform the policies, practices, and processes that will impact their patients and communities. This includes supporting and encouraging routine childhood vaccination within the primary care medical home – which will create opportunities to administer COVID-19 alongside holistic primary care services including access to other recommended vaccines, counsel on immunization, and provision of well child and mental health care.
2. Reassess assets and reopen the National Vaccine Program Office (NVPO) to centralize assets and coordinate with the forthcoming HHS Children’s Coordinating Council in the Office of the Secretary
With the urgent needs driven by COVID-19, the current assets within the government should be better centralized so that agencies that have subject matter experts and/or vaccine “leads” can coordinate their efforts within and across agencies. For example, the former National Vaccine Program Office within HHS, which the previous administration combined with the HIV/AIDS effort to create the Office of Infectious Disease and HIV/AIDS Policy (OIDP), could be reinstated and focused on developing guidance and technical support on vaccine communications. Even with limited resources within that group, an existing interagency vaccine task force is developing the nation’s immunization strategy for 2021-2025.
3. Create, disseminate, and amplify unified messages on all matters related to COVID-19 response
While the science on COVID-19 vaccines, testing, PPE, masking, treatment and coordination of care has been consistent and clear, information about that science has lacked the clarity and consistency required to make such science common knowledge. An overarching public health communication strategy must center on trusted messengers who present layered, affirming, and clear messages to normalize testing, masking, vaccination and treatment. This should be done alongside processes that democratize access to these pillars of the pandemic response.To be frank, the CDC has lost a concerning amount of public and professional confidence as this trusted messenger. Platforming and elevating new voices will require evaluating and amending current vaccine communications, ensuring messages are consistent for diverse audiences across agency websites, and leveraging various communication channels and messengers to spread the information. These messengers should include school-based champions of critical messages (administration, school-based clinics and nurses) community-based organizations, faith-based organizations and local community leaders and other trusted groups.
Another communication challenge that has emerged is that changes to clinical guidance have not been clear or well-disseminated. Specific attention should be paid to enhancing relationships and improving communications between federal agencies and state and local officials implementing the response, including more permissive guidance on how states and locals can use federal funding to resource community-based organizations to do outreach and education. This will be critical as COVID-19 is part of our day-to-day lives and in preparing for the next large-scale health crisis.
Clear, unified messaging has the power to undermine long-term efforts seeking to diminish the public credibility of government agencies and , under-resource, dismantle and remove the authority of these agencies. In the face of such anti-democratic efforts, public health systems must proactively move in tandem to shore up their legitimacy and proclaim their impact.
4. Establish a strategic roadmap to combat vaccine disinformation and build vaccine literacy
The COVID-19 vaccine roll out has served as an evolving opportunity to disseminate misinformation about vaccines, coordinate disinformation attacks about COVID-19, and launch anti-democratic campaigns more generally. Anti-science has gained traction, at least in part, because of insufficient vaccine and health literacy that predates the pandemic. This challenge is likely to worsen as state and federal governments move beyond “warp speed.” In addition, the current checkerboard of mandates for masks and vaccines, along with the inherent complexity across available vaccines and therapeutics authorized and approved by the FDA, together foster confusion and hinder care uptake, particularly among communities already under-served by the existing health information landscape Indigenous, Black, AAPI, Latina/o/e, and other communities of color.
Given this context, and the history that precedes it, pandemic/endemic response leaders must put forth a comprehensive plan to combat disinformation and advance population health literacy. That response might begin with implementing the recommendations set forth in the Surgeon General’s report on combating misinformation, creating policy that mandates social media algorithms boost credible science, funding research to understand how misinformation spreads and mitigate its consequences, and generating multiple strategies to discredit, combat, and dismantle sources of disinformation that harm consumers.
This response should also consider ways to enhance and amplify positive messages from trusted sources. Inspiration can be drawn from examples such as the Youth Anti-Drug Campaign or tobacco control efforts. Substantial federal government resources will be required for this effort to have a meaningful impact on vaccination rates, particularly among critical demographics like school-aged children.
This response should be paired with ongoing work to advance broader vaccine and health literacy and emphasize the need for routine and seasonal childhood vaccinations and regular wellness checks. Boosting population health literacy also requires confronting the pay walls and administrative barriers that block lay persons from consuming science texts and journal articles. It requires new laws to ensure the results of all federally-funded research are made available to the public, for free, in perpetuity, independent of the presidential administration. It requires the continual creation of proactive information campaigns to target emerging infectious threats before they become public health crises.
This collective work will require the Administration and government agencies, businesses, professional societies – including pediatric medical societies – and community-based organizations, schools and community health worker partners to work together.
5. Increase data surveillance and tracking
The CDC continues to mishandle tracking cases of COVID-19 infection. While the U.S. may approach one million cases/day of Omicron, CDC isn’t tracking cases domestically with the precision that the Weather Service tracks storms. Much has been made about outdated technology and methods used for disease reporting prior to and in the early stages of the pandemic, but progress remains slow. Decisions about what data is being collected and reported on (e.g., breakthrough cases) have been poorly communicated and a source of frustration for health officials and the public. CDC’s patchwork disease reporting system is in the process of a major overhaul. Still, without good surveillance data that instills confidence in our ability to offer guidance, course correct, and communicate accurately, the Administration appears to be under-resourced and uncoordinated. Increasing data surveillance and tracking, including strengthening reporting requirements around state-level data and funding improvements in local and state public health data infrastructure, should be an immediate priority.
6. Foster workforce leadership and effective community-driven best practices
Critical to this next phase is intentional coordination of efforts centered around the experiences of a diverse workforce with trusted providers of health information and services, coupled with trusted “health extenders” (e.g., trusted messengers in populations with lower vaccine uptake). By developing a regular “situation room” type convening that involves members of United States government (Executive Office of the President, Department of Education, HHS including CDC, HRSA, ACF), public health departments, school-based health, and community partners, the Administration can focus on diffusing accurate messages on what is working, what needs a course correction, fostering peer-to-peer learning and what can be speedily spread and scaled elsewhere.
Additionally, the Administration should leverage Medicaid redetermination grants funded by CMS and existing HRSA, OMH, and CDC COVID-related funding for state, local, tribal, and territorial health departments, CBOs, national nonprofits, and community health workforces to support unified messaging, goal-setting, training, and strategies focused on childhood vaccines tailored for these key partners. This will ensure we capitalize on opportunities at vaccination sites and ongoing community engagement to address concerns, advance family vaccine literacy and support referrals to primary care/pediatrics
7. Protect vaccinations, including the COVID-19 vaccines from commercialization to ensure their equitable distribution
The federal government has indicated that, absent additional congressional funding, it may run out of funding to purchase COVID vaccines by the end of 2022. This is unacceptable. Yet, conversations have been initiated about the process for ending universal purchase of COVID vaccine by the federal government and commercializing the vaccines. This process would shift financial burdens to the insurance marketplace, including private payers, Medicaid, and the Children’s Health Insurance Program, which will, with near certainty exacerbate existing inequities in vaccine access. Commercializing life-saving vaccines, particularly during an ongoing pandemic and in the face of emerging vaccine preventable diseases, also risks undermining the role of public health entities in effectively guaranteeing vaccine distribution and administration for the population.
In the absence of other exemplary programs to provide free vaccinations for adult populations, the Vaccines for Children Program (VFC) must become the national standard for all vaccine distribution and a central focus of the COVID vaccine strategy for children.But since COVID vaccines for some age groups are still being offered under an FDA emergency use authorization rather than full approval, these vaccines are not presently eligible for inclusion in the Vaccines for Children (VFC) program.
It is essential that the federal government extend the COVID-19 funding for vaccines so that children can access them as adults can, and appropriately shift all plans for commercialization to universal vaccine access for children and adults in the US.
8. Encourage and fund greater vaccine administration in primary care practices
As the country moves into a new stage of the COVID-19 pandemic, the federal government must intensify efforts to increase child vaccination rates for both COVID-19 and routine immunizations. Administering COVID-19 and routine vaccines has become increasingly complex, especially with the introduction of the bivalent COVID-19 booster at the same time as the flu vaccine roll out. Many pediatric practices are struggling to keep up with the increased need for counseling patients and families during a time when they are short staffed, to stay abreast of changing vaccine ordering logistics and labeling, to maintain cold storage space, and to follow conflicting messages on wastage for COVID-19 and routine vaccines. The administration must continue to ensure appropriate provider payment for vaccine counseling for both COVID-19 vaccines and routine immunizations, whether a vaccine is administered or not.
To help relieve some of the administrative burden currently associated with administering COVID-19 vaccines and participating in the Vaccines for Children (VFC) program, the federal government should ease requirements for practices, including the process and coding complexity for documentation of storage, and should promote best practices for state vaccine distribution such as distributing smaller quantities of vaccine. The Administration should also facilitate the availability and use of single-dose vials, as this will help increase provider adoption, reduce the amount of wasted COVID-19 vaccine, and ensure the feasibility of successful commercialization. Efforts to streamline and encourage the delivery of COVID vaccines in pediatric practices must occur hand-in-hand with federal government efforts to promote the need for COVID-19 and routine immunizations at the national level, as well as at a more targeted community level that can reduce disparities by reaching populations with lower vaccination rates.
These immediate action steps have the potential to change the course of the national COVID-19 response and also lay the groundwork for a stronger, more equitable pandemic response and public health infrastructure. Our Working Group welcomes questions and feedback related to these recommendations, as well as opportunities to facilitate or support their implementation. While some recommendations are more challenging than others, we must – and can – act now and work collaboratively in new ways to protect our children and families.
The Vaccine Equity Cooperative facilitated a diverse working group of subject matter experts which produced a set of detailed recommendations for the equitable distribution of COVID-19 vaccines to children ages 5-11 years old.
CHILDREN’S VACCINE EQUITY WORKING GROUP:
- Katherine A. Beckmann, PhD, MPH, Program Officer, Children, Families, and Communities, The David and Lucile Packard Foundation
- Rhea Boyd, MD, MPH, Pediatrician and child and community health advocate and scholar
- Robert Boyd, MDiv and MCRP, President/CEO, School-Based Health Alliance
- Caroline Brunton, MPH, JD, Program Officer, W.K. Kellogg Foundation
- Mark Del Monte, JD, CEO/Executive Vice President, American Academy of Pediatrics
- Tene Hamilton Franklin, MS, Vice President of Health Equity and Stakeholder Engagement, Health Leads
- Jann Jackson, MS, Senior Associate, Annie E. Casey Foundation
- Bruce Lesley, President, First Focus on Children
- Denise Octavia Smith, MBA, CHW, PN, Executive Director, National Association of Community Health Workers
- Alexandra Quinn, MA, CHW, CEO, Health Leads
- Scott C. Ratzan MD, MPA, Editor-in-Chief, Journal of Health Communication: International, Perspectives; Professor at CUNY School of Public Health and Health Policy, Columbia University Mailman School of Public Health, Tufts University School of Medicine
- Lauren A. Smith, MD, MPH, Chief Health Equity and Strategy Officer, CDC Foundation
- Monica Valdes Lupi, JD, MPH, Managing Director, Kresge Foundation
- Lisa Waddell, MD, MPH, Chief Medical Officer, CDC Foundation
- Sean Yoo, Chief of Staff, Health Leads
FURTHER INPUT FROM AND SPECIAL THANKS TO:
- James Baumberger, Senior Director, Federal Advocacy, American Academy of Pediatrics
- Erica DeWald, Chief Communication Officer, Vaccinate Your Family
- Julie Morita, Executive Vice President, Robert Wood Johnson Foundation
Tags: health equity, COVID-19, vaccines